Depression, Apolipoprotein E Genotype, and the Incidence of Mild Cognitive Impairment

A Prospective Cohort Study

Yonas E. Geda, MD; David S. Knopman, MD; David A. Mrazek, MD; Gregory A. Jicha, PhD, MD; Glenn E. Smith, PhD; Selamawit Negash, PhD; Bradley F. Boeve, MD; Robert J. Ivnik, PhD; Ronald C. Petersen, PhD, MD; V. Shane Pankratz, PhD; Walter A. Rocca, MD, MPH

Background: It remains unknown whether depression and apolipoprotein E genotype are risk factors for incident mild cognitive impairment (MCI).

Objective: To determine whether elderly individuals with depression (measured by the short Geriatric Depression Scale) are at increased risk of developing incident MCI.

Design: Prospective cohort study.

Setting: Primary care clinic.

Participants: A cohort of 840 cognitively normal elderly subjects without depression at recruitment who were followed up prospectively for a median of 3.5 years (range, 0.4-12.8 years). Subjects who developed depression (score of ≥6 on the short Geriatric Depression Scale; depression cohort) were compared with all remaining subjects (referent cohort).

Main Outcome Measures: Incidence of MCI (primary outcome) and incidence of MCI or dementia (composite secondary outcome).

Results: Individuals in the depression cohort were at significantly increased risk of subsequent incident MCI (hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.2-4.1) after adjusting for age (time scale), sex, and education, and considering dementia as a competing outcome. The association was stronger in men but did not vary by severity of depression. We observed a synergistic interaction between apolipoprotein E genotype (ε3/ε4 or ε4/ε4) and depression (joint effect HR, 5.1; 95% CI, 1.9-13.6; test for additive interaction, P = .03). We found a similar association between depression and the subsequent composite outcome of incident MCI or dementia (HR, 2.6; 95% CI, 1.6-4.3).

Conclusions: Cognitively normal elderly individuals who develop depression are at increased risk of subsequent MCI. We found a synergistic interaction between depression and apolipoprotein E genotype.

Arch Neurol. 2006;63:435-440

Methods

STUDY PARTICIPANTS

Normal elderly persons have been recruited by the Mayo Alzheimer Disease Patient Registry for longitudinal studies of cognitive aging since 1986. This cohort has been described in detail in previous publications.12,13 All subjects were residents of Olmsted County, Minnesota, and were receiving their routine medical care at the Division of Primary Care Medicine of the Mayo Clinic, Rochester, Minn. Potential normal individuals were referred to Alzheimer Disease Pa...
ELIGIBILITY CRITERIA

Normal cognitive status was defined using the published criteria of the Mayo's Older American Normative Studies (MOANS) and required normal functioning in the community and no cognitive impairment. We excluded persons with a neurologic or psychiatric condition judged to interfere with cognitive assessment at the time of recruitment, such as depression. However, a history of depression was not an exclusion criterion. We also excluded persons receiving psychoactive medications in amounts that could compromise cognition. By contrast, persons with comorbid illnesses such as hypertension and coronary artery disease and those receiving medications for these disorders were included. However, if the primary care physician considered these illnesses or their treatments to interfere with cognitive functions, the persons were excluded.

MEASURE OF DEPRESSION

Participants were followed up longitudinally with repeated visits every 12 to 18 months. The follow-up visits included a clinical evaluation and the administration of an abbreviated neuropsychological battery. Depression was assessed by using the short version of the GDS (15 items). Study participants who developed depression (score of ≥6 on the GDS at least once) before reaching one of the outcomes of interest (MCI or dementia) were considered to be in the depression cohort starting on the date of the testing. All remaining participants who never developed depression (as per GDS score) were considered to be in the referent cohort. The depression and referent cohorts were followed up longitudinally to study the incidence of MCI. In addition, for each person in the study we obtained a history of depression preceding enrollment in the study. This historical information was obtained using the medical records–linkage system of the Rochester Epidemiology Project. Details about the system were reported elsewhere. 24

APOE GENOTYPE

Blood was drawn from the study participants after receiving informed consent. DNA was amplified by means of polymerase chain reaction, and APOE genotyping was determined by standard methods, as reported in detail elsewhere. The genotypes were determined by laboratory technicians who were kept unaware of clinical characteristics (eg, presence of depression or MCI).

OUTCOME MEASURES

The primary outcome was MCI. The adjudicating team diagnosed MCI on the basis of psychometric data collected during the follow-up visits and according to the criteria of Petersen et al25 (memory complaint, normal activities of daily living, normal general cognitive function, abnormal memory for age, and a 1.5 SD deviation from the mean of the cohort on the short test of mental status examination). Sensitivity analyses were also conducted using criteria proposed by the National Institute of Aging and Alzheimer's Disease Association Task Force26 (normal activities of daily living, normal scores on the short form of the GDS, and normal scores on the Hachinski Ischemic Scale,16 and 6 or fewer points on the 11-item Geriatric Depression Scale). Because the follow-up visits occurred only every 12 to 18 months, a participant could develop dementia without any evidence of transition through an MCI status. Therefore, we considered as a secondary outcome measure the composite event of incident MCI or dementia. The adjudicating team diagnosed dementia according to Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria.30

STATISTICAL ANALYSIS

For survival analyses, baseline was the date of enrollment in the study for the referent cohort and the date on which depression was first measured (GDS score ≥6) for the depression cohort. Subjects were censored at death, loss to follow-up, or the end of the study (whichever came first). In analyses for MCI, dementia was considered a competing outcome.31 The association between the independent variable (depression measured by GDS) and the outcome of incident MCI was assessed using Cox proportional hazards models adjusted for sex and education (≥12 vs ≤12 years). For more stringent age adjustment, age was used as the time scale in the survival analyses. However, graphic display of cumulative incidence curves was based on the more conventional time-to-event scale (accounting for competing outcomes). The same type of analysis was conducted for the composite event of incident MCI or dementia (secondary analysis). Stratified analyses were conducted for men and women separately and by level of severity of depression (GDS scores of 6 and 7-15 vs 0-5). Possible interaction effects with APOE genotype were examined using multivariate models to test for both multiplicative and additive interactions. This same method was also used to test for interaction between newly developed depression as measured by the GDS and a history of depression preceding enrollment in the study (preceding baseline). In addition, we compared the distribution of the individual GDS items in depressed subjects who developed MCI or dementia and in those who did not, to identify the most predictive items.

Statistical testing was conducted at the conventional 2-tailed α level of .05. Analyses were conducted using SAS (SAS Institute Inc, Cary, NC) and S-Plus (Insightful Corp, Seattle, Wash) statistical software.

RESULTS

Longitudinal data were available for 840 participants, who were free of both cognitive impairment and depression at the time of enrollment into the study and were followed up for a median of 3.5 years (range, 0.4-12.8 years). A total of 143 participants (17.0%) developed depression during follow-up (depression cohort), while 697 (83.0%) did not
Table 1. Demographic and Clinical Characteristics of Study Subjects

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Referent Cohort (n = 697)</th>
<th>Depression Cohort (n = 143)</th>
<th>Overall Group (N = 840)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at baseline, median (range), y</td>
<td>77 (50-98)</td>
<td>84 (65-102)</td>
<td>78 (50-102)</td>
</tr>
<tr>
<td>Education, median (range), y</td>
<td>13 (5-20)</td>
<td>12 (6-20)</td>
<td>13 (5-20)</td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td>421 (60.4)</td>
<td>98 (68.5)</td>
<td>519 (61.8)</td>
</tr>
<tr>
<td>MMSE score, median (range)</td>
<td>28 (22-30)</td>
<td>28 (14-30)</td>
<td>28 (14-30)</td>
</tr>
<tr>
<td>DRS score, median (range)</td>
<td>137 (107-144)</td>
<td>136 (88-144)</td>
<td>137 (88-144)</td>
</tr>
<tr>
<td>Follow-up time, median (range), y</td>
<td>3.5 (1.0-12.8)</td>
<td>2.6 (0.4-12.3)</td>
<td>3.5 (0.4-12.8)</td>
</tr>
<tr>
<td>History of depression, No. (%)</td>
<td>184 (26.4)</td>
<td>82 (57.3)</td>
<td>266 (31.7)</td>
</tr>
<tr>
<td>APOE genotype, No. (%)</td>
<td>e4/e4 12 (1.7)</td>
<td>2 (1.4)</td>
<td>14 (1.7)</td>
</tr>
<tr>
<td></td>
<td>e3/e4 164 (23.5)</td>
<td>24 (16.8)</td>
<td>188 (22.4)</td>
</tr>
<tr>
<td></td>
<td>e3/e3 412 (59.1)</td>
<td>84 (58.7)</td>
<td>496 (59.0)</td>
</tr>
<tr>
<td></td>
<td>Other† 108 (15.5)</td>
<td>33 (23.1)</td>
<td>141 (16.8)</td>
</tr>
</tbody>
</table>

Abbreviations: APOE, apolipoprotein E; DRS, Dementia Rating Scale; MMSE, Mini-Mental State Examination.
*Subjects without depression constituted the referent cohort (Geriatric Depression Scale [GDS] score <6); subjects with depression, the depression cohort (GDS score ≥6); subjects with depressive symptoms but not a history of depression, the study cohort (GDS score =6) who subsequently developed depression (depression cohort).
†Baseline was the date of enrollment in the study for subjects in the referent cohort and the date on which depression was first measured (GDS score ≥6) for subjects in the depression cohort.
‡Information was missing for 3 subjects.
§Information was missing for 7 subjects.
‖History of depression preceding enrollment in the study.
¶Information was missing for 1 subject in the referent cohort.

The association between depression and MCI was stronger in men (HR, 4.5; 95% CI, 1.8-11.3) than in women (HR, 1.5; 95% CI, 0.7-3.6); however, the difference was not statistically significant. The cumulative incidence of MCI did not increase with increasing severity of depression (GDS scores of 6 and 7-15 vs 0-5; data not shown). In addition, we found no significant difference in the duration of depressive symptoms between depressed subjects who developed incident MCI or dementia (median, 2.4 years; range, 0.6-8.2 years) and those who

Figure 1. Cumulative incidence curves of mild cognitive impairment (MCI) (A) dementia was considered as a competing outcome) and MCI or dementia (B) for subjects with depression (depression cohort) and without depression (referent cohort). The graph does not correct for differences in age at baseline between the depression and referent cohorts (conventional time-to-event scale); however, the hazard ratio estimates reported in the text were corrected for age and for other potential confounders.
did not (median, 2.8 years; range, 0.4-12.3 years; \( P = .2 \)). The association between depression and MCI increased when \( \text{APOE} \) genotype was included in the model (\( \varepsilon 3/\varepsilon 4, \varepsilon 4/\varepsilon 4 \), or otherwise). The HR for depression was 2.3 (95% CI, 1.2-4.3); for \( \text{APOE} \) \( \varepsilon 4/\varepsilon 4 \), 4.4 (95% CI, 1.0-19.0); and for \( \text{APOE} \) \( \varepsilon 3/\varepsilon 4 \), 1.7 (95% CI, 0.9-3.2).

Of 14 subjects with the \( \varepsilon 4/\varepsilon 4 \) genotype, 2 (14.3%) developed MCI and 1 (7.1%) dementia. Of 188 subjects with the \( \varepsilon 3/\varepsilon 4 \) genotype, 14 (7.4%) developed MCI and 15 (8.0%) dementia. Of 637 subjects with the \( \varepsilon 3/\varepsilon 3 \) or other rarer genotypes, 34 (5.3%) developed MCI and 31 (4.9%) dementia. We conducted analyses for interaction using subjects who did not carry either the \( \varepsilon 3/\varepsilon 4 \) or \( \varepsilon 4/\varepsilon 4 \) genotype and who did not have depression as the reference group. Compared with the reference group, subjects with depression but no \( \varepsilon 3/\varepsilon 4 \) or \( \varepsilon 4/\varepsilon 4 \) had an HR for MCI of 1.9 (95% CI, 0.9-4.1), subjects without depression but with \( \varepsilon 3/\varepsilon 4 \) or \( \varepsilon 4/\varepsilon 4 \) had an HR of 1.6 (95% CI, 0.8-3.4), and subjects with the joint effect of depression and \( \varepsilon 3/\varepsilon 4 \) or \( \varepsilon 4/\varepsilon 4 \) had an HR of 5.1 (95% CI, 1.9-13.6). A test for additive interaction was significant (\( P = .03 \); synergistic interaction), whereas a test for multiplicative interaction was not.

### Table 2. Survival Analyses to Investigate the Possible Interaction Between Depression and \( \text{APOE} \) Genotype in Their Association With MCI

<table>
<thead>
<tr>
<th>Sample or Stratum</th>
<th>No. at Risk</th>
<th>No. With MCI</th>
<th>Median Time in Study, y</th>
<th>HR (95% CI)</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No depression and no ( \varepsilon 3/\varepsilon 4 ) or ( \varepsilon 4/\varepsilon 4 ) genotype</td>
<td>512</td>
<td>22</td>
<td>3.6</td>
<td>1.0</td>
<td>\n</td>
</tr>
<tr>
<td>Depression but no ( \varepsilon 3/\varepsilon 4 ) or ( \varepsilon 4/\varepsilon 4 ) genotype</td>
<td>103</td>
<td>12</td>
<td>2.6</td>
<td>1.9 (0.9-4.1)</td>
<td>.08</td>
</tr>
<tr>
<td>Depression and ( \varepsilon 3/\varepsilon 4 ) or ( \varepsilon 4/\varepsilon 4 ) genotype</td>
<td>25</td>
<td>5</td>
<td>2.4</td>
<td>5.1 (1.9-13.6)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

**Abbreviations:** \( \text{APOE} \), apolipoprotein E; CI, confidence interval; HR, hazard ratio; MCI, mild cognitive impairment.

*Data on \( \text{APOE} \) genotype were missing for 1 person.

†Calculated using Cox proportional hazards models considering dementia as a competing outcome, with age as the time scale and with adjustment for sex (male sex: HR, 1.8; 95% CI, 1.0-3.2; \( P = .07 \)) and education (\( \geq 12 \) y: HR, 0.9; 95% CI, 0.4-1.9; \( P = .8 \)). A test for additive interaction was significant (\( P = .03 \)).

COMMENT

In this prospective cohort study, depression more than doubled the risk of transition from normal cognitive aging to incident MCI after controlling for age (time scale), education, and sex. The risk was similarly increased when the composite outcome of incident MCI or dementia was considered. The association was stronger in men than women, but did not vary by severity of depression. It is surprising that there was no relationship between the severity of depressive symptoms and the risk of MCI. However, most of the subjects who developed depression in this cohort had mild or moderate depression (GDS scores of 6 or 7-11). In addition, the GDS may be inadequate to measure severity because the score increases by the number of items endorsed rather than by the severity of the items.

We found an antagonistic (negative) interaction between depression newly developed during the study and history of depression preceding the study. Subjects who developed depression during the study and also had a history of depression had a smaller risk of MCI than those who developed depression but had no history of depression. This pattern of interaction may suggest a protective effect of antidepressant medications used before recruitment by subjects with a history of depression. Unfortunately, we could not test this hypothesis because we did not collect data on antidepressant medications used either before or during the study.

We also observed a synergistic (positive) interaction between \( \text{APOE} \) genotype and depression: the joint effect of depression and \( \text{APOE} \) genotype was significantly greater than the sum of the independent effects of the 2 factors. We propose the following 4 alternative mechanisms that may account for the observed association between depression (GDS score \( \geq 6 \)) and incident MCI (Figure 2).

1. **Causal factor.** Depression is in the chain of causality leading to MCI by virtue of its effect on the neuroendocrine axis. An important implication of this hypothesis is that an intervention targeting depression may lead to primary prevention of MCI.

2. **Shared risk factor or confounding.** Depression is non- causally associated with MCI because a third factor leads to the genesis of both MCI and depression. The third factor (confounder) could be genetic, environmental, or both.

3. **Reverse causality.** First, a person who is experiencing some degree of cognitive decline may develop depression as a reaction to the symptoms. Second, depressive symptoms may be an early noncognitive manifestation of dementia. Third, depression may “unmask” the clinical manifestations of MCI in individuals with limited cognitive reserve.

4. **Interaction.** Depression leads to cognitive decline only in the presence of a genetic susceptibility factor or another risk factor. We found evidence of a synergistic interaction between \( \text{APOE} \) genotype and depression.

These 4 mechanisms (and other possible mechanisms) are not mutually exclusive and may act in combination.

The individual items of the GDS that were significantly more endorsed by depressed subjects destined to later develop MCI or dementia were items 10 (memory) and 13 (energy). These 2 items refer to premorbid symptoms of later cognitive decline or illness in general rather than to mood symptoms per se.

Few prospective studies have investigated the association between depression and dementia, and the results of these studies have been inconsistent. To our knowledge, ours is one of the first studies to investigate...
the association between depression and incident MCI as measured by the criteria of Petersen et al.2 Our secondary outcome of incident MCI or dementia is comparable to the outcome used in the Religious Orders Study33 and in the Baltimore Longitudinal Study of Aging.35 In those studies, subjects with depression were more likely than referent subjects to become demented or to experience cognitive decline.35,36

There are several strengths to our study. First, the longitudinal follow-up of a large cohort of elderly individuals free of both cognitive impairment and depression on enrollment enabled us to observe the association between the independent variable (depression) and the primary outcome of incident MCI. Second, the frequency of follow-up visits was high (every 12-18 months). This allowed us to detect depression and MCI or dementia near the time of their onset (incident events). Third, we adjusted for the difference in age at baseline between depressed and referent subjects by using age as the time scale in survival analyses.31 Traditional time-to-event survival analyses were also conducted for comparison and showed similar results (sensitivity analyses; data not shown).31 Fourth, available genotyping data allowed for the exploration of a possible interaction between APOE genotype and depression.

Our study also had limitations. First, we did not use a structured interview in the assessment of depression, and we did not collect information about treatments for depression. We measured depression using the short version of the GDS (15 items) rather than the original long version (30 items).9,12,13 However, the short version has been validated and shown to be comparable to the long version.13 Second, because of our stringent eligibility criteria, the subjects included in our sample may have been healthier than a probability (random) sample of elderly individuals residing in the community. This may have reduced the external validity of our study. A future population-based study can rectify this weakness. Third, despite the high frequency of follow-up visits, we may have missed individuals who transitioned from normal cognition to dementia between 2 visits. To account for these incomplete assessments, we assumed that all subjects who developed dementia went through an MCI stage, and we used a composite secondary outcome measure of MCI or dementia.

Our study suggests that cognitively normal elderly individuals who develop depression are at increased risk of subsequent MCI. In addition, there may be a synergistic interaction between APOE genotype and depression.

Accepted for Publication: November 1, 2005.
Correspondence: Yonas E. Geda, MD, Department of Psychiatry, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (geda.yonas@mayo.edu).

Author Contributions: Study concept and design: Geda, Petersen, and Rocca. Acquisition of data: Geda, Knopman, Jicha, Smith, Boeve, and Ivnik. Analysis and interpretation of data: Geda, Knopman, Smith, Negash, Boeve, Petersen, Pankratz, and Rocca. Drafting of the manuscript: Geda, Knopman, Petersen, and Rocca. Critical revision of the manuscript for important intellectual content: Geda, Knopman, Mrazek, Jicha, Smith, Negash, Boeve,

REFERENCES
